ArticleCommunications biology2026
Pyruvate carboxylase promotes SREBP1a-mediated lipid synthesis in epithelial ovarian cancer.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Epithelial ovarian cancer (EOC) is characterized by late diagnosis and high recurrence, with dysregulated lipid metabolism emerging as a hallmark of progression. Here, we identify pyruvate carboxylase (PC) as a key metabolic driver that promotes lipid synthesis in EOC. PC is upregulated in EOC tissues and correlates with poor prognosis and triglyceride accumulation. Mechanistically, PC enhances acetyl-CoA production, promoting sterol regulatory element-binding protein 1a (SREBP1a) acetylation and stability, and increases α-ketoglutarate levels to facilitate ten-eleven translocation 1 (TET1)-mediated DNA hydroxymethylation at lipid synthetase gene promoters. These dual effects augment SREBP1a recruitment and transcriptional activation of lipid synthesis genes. Pharmacological or genetic inhibition of PC, TET1, and SREBP1a, either individually or in combination, effectively suppresses lipid synthesis and tumor growth in vitro and Balb/c nude mouse xenografts. Our findings uncover a PC-TET1-SREBP1a metabolic-epigenetic axis for EOC lipid reprogramming and tumor progression, offering a potential therapeutic target to suppress ovarian cancer aggressiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.